Source: Annual Congress 2012 - Exacerbations of asthma and COPD: assessment, impact and novel treatments
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P.W. Jones, D. Singh, A. Agusti, E.D. Bateman, R. Lamarca, G. de Miquel, C. Caracta, E. Garcia Gil (London, Manchester, United Kingdom; Barcelona, Spain; Cape Town, South Africa). Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: Results from ATTAIN. Eur Respir J 2012; 40: Suppl. 56, 195

Member's Comments

No comment yet.

Related content which might interest you: Pooled analysis of twice-daily aclidinium bromide in COPD patients: Dyspnea and health status in the ACCORD-COPD I and ATTAIN trials Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 Tiotropium reduces COPD exacerbations: the MISTRAL study Source: Eur Respir J 2004; 24: Suppl. 48, 513s Year: 2004 Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Effect of salmeterol/fluticasone propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) Source: Annual Congress 2007 - Primary care respiratory problems Year: 2007 Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: Pooled analysis of phase III studies Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Effect of salmeterol/fluticasone propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality: INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations) study Source: Eur Respir J 2007; 30: Suppl. 51, 34s Year: 2007 Twice-daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010 Effect of tiotropium bromide on IFN-γ level: Results from 180-days study in moderate COPD patients with viral-induced exacerbations in anamnesis Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016 Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Tiotropium reduces health resource utilization associated with COPD exacerbations Source: Eur Respir J 2004; 24: Suppl. 48, 513s Year: 2004 Cost effectiveness of budesonide/formoterol vs fluticasone/salmeterol: Real-world effectiveness and safety in COPD Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Indacaterol/glycopyrronium (IND/GLY) is superior to salmeterol/fluticasone (SFC) in improving the health status of patients with moderate-to-very severe COPD: Results from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 ACCORD COPD I: Twice-daily aclidinium bromide improves quality of life and dyspnea in COPD patients Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 LATE-BREAKING ABSTRACT: Effect of fluticasone furoate (FF)/vilanterol (VI) on the rate of COPD exacerbations in everyday clinical practice: Results of the COPD Salford lung study (SLS) Source: International Congress 2016 – Best abstracts in asthma and COPD Year: 2016 Effect of telehealthcare on exacerbations and hospital admissions in COPD: A randomised controlled trial Source: International Congress 2015 – Best abstracts in pulmonary rehabilitation and chronic care Year: 2015 Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 Telehealthcare in COPD – A feasibility trial Source: International Congress 2016 – Non-inflammatory assessment of airway disorders Year: 2016 Indacaterol/glycopyrronium (IND/GLY) is more effective than salmeterol/fluticasone (SFC) in reducing exacerbations, regardless of outcome measurement utilised: Results from the FLAME study Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016